Pentobarbital will minimize the extent or result of gefitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. pentobarbital will lessen the level or outcome of lonafarnib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Lonafarnib is a sensitive CYP3A4 substrate. Coadministration with sturdy or average CYP3A4 inducers is contraindicated. pentobarbit... https://geronimoi293szh2.blog-gold.com/profile